ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024
Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06935838 (Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Non-communicable disease (NCD) risk among people living with HIV in KwaZulu-Natal, South Africa: evidence from a randomised trial of community-based differentiated service delivery.Journal of the International AIDS Society · 2025Trial
- DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-Based Regimen Switch Strategy to Manage Integrase Inhibitor-Related Weight Gain.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Trial
- Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.Annals of internal medicine · 2024Trial
- Weight gain and obesity management in people with HIV: pathophysiology, antiretroviral therapy effects, and clinical strategies.Topics in antiviral medicine · 2026Review
- Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments.Current HIV/AIDS reports · 2026Review
- The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy.Open forum infectious diseases · 2025Article
- Changes in Hepatic Steatosis Before and After Direct-Acting Antiviral Treatment in People With HIV and Hepatitis C Coinfection.The Journal of infectious diseases · 2025Article
- Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.Topics in antiviral medicine · 2024Review
- Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.American journal of preventive cardiology · 2024Review
- Weight Gain and Antiretroviral Therapy.Infectious disease clinics of North America · 2024Review
- Cardiometabolic health in people with HIV: expert consensus review.The Journal of antimicrobial chemotherapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWeight gain and associated metabolic complications are increasingly prevalent among people with human immunodeficiency virus (PWH). Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are incretin-based therapies for diabetes and weight management that have been shown to result in substantial weight loss; however, studies of their effects in PWH are limited.
methodsA retrospective single-center cohort study was conducted among PWH who were taking GLP-1RAs at the University of California, San Diego Owen Clinic between 1 February 2021 and 1 February 2023. Baseline clinical data were collected and changes in weight, body mass index (BMI), and hemoglobin A1C (A1C) before starting GLP-1RAs compared to the most recent clinic visit were calculated (with a minimum of 3 months follow-up time required). Logistic regression was performed to identify variables associated with >5% of total body weight loss.
resultsA total of 225 patients received on average 13 months of GLP-1RA therapy, with 85 (37.8%) achieving the maximum GLP-1RA dose. GLP-1RA therapy resulted, on average, in a weight loss of 5.4 kg, decrease in BMI by 1.8 kg/m2, and decrease in A1C by 0.6%. In the multivariable analysis, higher baseline BMI (odds ratio [OR], 1.10 [95% confidence interval {CI}, 1.03-1.16]), treatment duration of GLP-1RA therapy >6 months (OR, 3.12 [95% CI, 1.49-6.49]), and use of tirzepatide (OR, 5.46 [95% CI, 1.44-20.76]) were significantly more likely to be associated with >5% weight loss.
conclusionsUse of GLP-1RAs led to declines in weight, BMI, and A1C among PWH and offers an additional strategy to address weight gain and diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.